BlackRock Inc. increased its stake in Marinus Pharmaceuticals Inc (NASDAQ:MRNS) by 7.2% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,427,739 shares of the biopharmaceutical company’s stock after buying an additional 229,811 shares during the period. BlackRock Inc. owned 6.52% of Marinus Pharmaceuticals worth $14,226,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors also recently bought and sold shares of MRNS. Wells Fargo & Company MN grew its stake in shares of Marinus Pharmaceuticals by 199.6% in the 2nd quarter. Wells Fargo & Company MN now owns 52,642 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 35,072 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Marinus Pharmaceuticals by 32.7% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 126,761 shares of the biopharmaceutical company’s stock worth $527,000 after buying an additional 31,260 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of Marinus Pharmaceuticals by 1.9% in the 2nd quarter. Northern Trust Corp now owns 548,467 shares of the biopharmaceutical company’s stock worth $2,276,000 after buying an additional 10,204 shares during the last quarter. Institutional investors own 64.26% of the company’s stock.
Several analysts have commented on the company. ValuEngine upgraded Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, October 7th. Zacks Investment Research downgraded Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 10th. Mizuho cut their target price on Marinus Pharmaceuticals from $5.00 to $1.70 and set a “neutral” rating on the stock in a research note on Tuesday, July 23rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 target price on shares of Marinus Pharmaceuticals in a research note on Friday. Finally, HC Wainwright assumed coverage on Marinus Pharmaceuticals in a research note on Tuesday, September 3rd. They set a “buy” rating and a $5.00 target price on the stock. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Marinus Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $8.68.
Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.01). Equities analysts expect that Marinus Pharmaceuticals Inc will post -0.94 earnings per share for the current fiscal year.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Further Reading: Analyzing a company’s cash flow statement
Want to see what other hedge funds are holding MRNS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Marinus Pharmaceuticals Inc (NASDAQ:MRNS).
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.